Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1080/07391102.2020.1770127 http://scihub22266oqcxt.onion/10.1080/07391102.2020.1770127 32419646!7284139!32419646     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Biomol+Struct+Dyn 2021 ; 39 (10): 3793-3801 Nephropedia Template TP {{tp|p=32419646|t=2021. Design of multi-epitope vaccine candidate against SARS-CoV-2: a in-silico study |pdf=|usr=}}{{32419646}} gab.com Text Design of multi-epitope vaccine candidate against SARS-CoV-2: a in-silico study JO: J Biomol Struct Dyn http://www.kidney.de/pget.php?&tw=1&pmid=32419646 #FOAvip The best therapeutic strategy to find an effective vaccine against SARS-CoV-2 is to explore the target structural protein. In the present study, a novel multi-epitope vaccine is designed using in silico tools that potentially trigger both CD4 and CD8 T-cell immune responses against the novel Coronavirus. The vaccine candidate was designed using B and T-cell epitopes that can act as an immunogen and elicits immune response in the host system. NCBI was used for the retrieval of surface spike glycoprotein, of novel corona virus (SARS-CoV-2) strains. VaxiJen server screens the most important immunogen of all the proteins and IEDB server gives the prediction and analysis of B and T cell epitopes. Final vaccine construct was designed in silico composed of 425 amino acids including the 50S ribosomal protein adjuvant and the construct was computationally validated in terms of antigenicity, allergenicity and stability on considering all critical parameters into consideration. The results subjected to the modeling and docking studies of vaccine were validated. Molecular docking study revealed the protein-protein binding interactions between the vaccine construct and TLR-3 immune receptor. The MD simulations confirmed stability of the binding pose. The immune simulation results showed significant response for immune cells. The findings of the study confirmed that the final vaccine construct of chimeric peptide could able to enhance the immune response against nCoV-19. Twit Text FOAVip Design of multi-epitope vaccine candidate against SARS-CoV-2: a in-silico study ????J Biomol Struct Dyn http://www.kidney.de/pget.php?&tw=1&pmid=32419646 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32419646 #FOAvip English Wikipedia <ref>{{Cite pmid|32419646}}</ref> Design of multi-epitope vaccine candidate against SARS-CoV-2: a in-silico study #MMPMID32419646 Abraham Peele K; Srihansa T; Krupanidhi S; Ayyagari VS; Venkateswarulu TC J Biomol Struct Dyn 2021[Jul]; 39 (10): 3793-3801 PMID32419646show ga The best therapeutic strategy to find an effective vaccine against SARS-CoV-2 is to explore the target structural protein. In the present study, a novel multi-epitope vaccine is designed using in silico tools that potentially trigger both CD4 and CD8 T-cell immune responses against the novel Coronavirus. The vaccine candidate was designed using B and T-cell epitopes that can act as an immunogen and elicits immune response in the host system. NCBI was used for the retrieval of surface spike glycoprotein, of novel corona virus (SARS-CoV-2) strains. VaxiJen server screens the most important immunogen of all the proteins and IEDB server gives the prediction and analysis of B and T cell epitopes. Final vaccine construct was designed in silico composed of 425 amino acids including the 50S ribosomal protein adjuvant and the construct was computationally validated in terms of antigenicity, allergenicity and stability on considering all critical parameters into consideration. The results subjected to the modeling and docking studies of vaccine were validated. Molecular docking study revealed the protein-protein binding interactions between the vaccine construct and TLR-3 immune receptor. The MD simulations confirmed stability of the binding pose. The immune simulation results showed significant response for immune cells. The findings of the study confirmed that the final vaccine construct of chimeric peptide could able to enhance the immune response against nCoV-19. |*COVID-19 Vaccines[MESH] |*COVID-19/prevention & control[MESH] |*Epitopes, B-Lymphocyte/immunology[MESH] |*Epitopes, T-Lymphocyte/immunology[MESH] |Humans[MESH] |Molecular Docking Simulation[MESH] |SARS-CoV-2[MESH] |Spike Glycoprotein, Coronavirus/immunology[MESH]Design of multi-epitope vaccine candidate against SARS-CoV-2: a in-sil(epmc).pdf DeepDyve Pubget Overpricing